daptomycin (Cubicin)
Jump to navigation
Jump to search
Introduction
Tradename: Cubicin (New agent 2003)
Indications
- bacterial infections due to susceptible organisms
- complicated skin infections* due to gram positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA)
- Staphylococcus aureus bacteremia, sepsis
- endocarditis, including right sided endocarditis caused by MSSA & MRSA
- investigational: vancomycin-resistant enterococci (VRE)
* works about as well as vancomycin, oxacillin or nafcillin for treating complicated skin infections
Contraindications
- bound by pulmonary surfactant, thus not effective in treatment of staphylococcal pneumonia[5]
Dosage
* Cubicin & Cubicin RF reconstituted from powder differently
- sodium chloride solution for Cubicin
- either sterile or bacteriostatic water for injection for Cubicin RF
- storage different as well (see instructions)
Monitor
serum creatinine & serum creatine kinase weekly during treatment
Adverse effects
- myopathy, increased serum CK (25%)
- peripheral neuropathy (10%)[2]
- resistance develops in 1/3 of patients with persistently positive cultures[2]
- risk of eosinophilic pneumonia[4]
Drug interactions
- possible increased risk of myopathy when used in combination with statin (consider temporarily discontinuing statin)
Mechanism of action
More general terms
References
- ↑ Prescriber's Letter 10(11):63 2003
- ↑ 2.0 2.1 2.2 Fowler VG Jr et al, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16914701
Grayson ML The treatment triangle for staphylococcal infections N Engl J Med 2006, 355:724 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16914709 - ↑ Arbeit RD et al, The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673 PMID: https://www.ncbi.nlm.nih.gov/pubmed/15227611
- ↑ 4.0 4.1 FDA MedWatch, 07/29/2010 Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm220499.htm
- ↑ 5.0 5.1 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18. American College of Physicians, Philadelphia 2012, 2015, 2018.
- ↑ Lowes R New FDA Watch List Flags More Drugs Medscape Internal Medicine. July 3, 2017 http://www.medscape.com/viewarticle/882425
- ↑ Cervera C, Sanroma P, Gonzalez-Ramallo V et al Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial). Infect Dis (Lond). 2017 Mar;49(3):200-207. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27820968
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16129629
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16134395
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=21585658
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=46930993
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16129688
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=57336511
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71311849
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25246315